EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Convalescent Coronavirus Disease 2019 Plasma Donor Profile: A Tertiary Care Hospital-based Study

Chandrika Rao, Sajitha Kaliyath, Ashlesha Jakkampudi

Biomedical and Biotechnology Research Journal · 2023

DOI: 10.4103/bbrj.bbrj_102_23 ↗
AbstractBibliografische Angaben

Abstract

Background: Currently, there is no specific treatment for coronavirus infections. Many trials are investigating the safety and efficacy of COVID-19 convalescent plasma (CCP) in critically ill coronavirus disease 2019 (COVID-19) patients. Case reports and case series have shown encouraging results. This retrospective study reports the Indian experience of CCP donor selection and donations. Methods: The donors aged 18-60 who had recovered from COVID-19 at least 28days before were recruited for COVID-19 convalescent plasma donation between August to December 2020. Results: During the period, 201 of 205 donors recruited were judged eligible and underwent plasmapheresis procedures. Ninety-nine percent (200/201) of the CCP donors were male. The average time between recovery from symptoms and CCP donation was 71.15 (±29.6) days. Two hundred and one plasmapheresis procedures were performed with an average volume of 494 (±34.0) ml of collected plasma, divided into two subunits (total 402). Ninety-two percent of CCP donors at the time of plasma donation had anti-severe acute respiratory syndrome coronavirus-2 IgG titer of >6. Plasmapheresis-related adverse reactions occurred in 1.46% (3/205) of cases; all reactions were mild, and none required therapeutic intervention. Changes in IgG titer against S-protein showed an upward trend and positively correlated with time from the onset of disease symptoms to the plasma donation. Conclusion: This study demonstrates the feasibility and safety of a CCP donation program. Identifying factors positively associated with higher antibody titers at the time of donation may help optimize the selection of CCP donors.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →